Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Demand for weight-loss pills predicted to expand

Novo Nordisk expects the oral GLP-1 pill to grow the user base by overcoming injection barriers and reach over one-third of the market by 2030, CEO said.

Summary by The West Australian
An oral version of weight-loss medication Wegovy could expand treatment to groups like men and younger patients, a Novo Nordisk executive ​says.

7 Articles

CNBCCNBC
Center

Novo Nordisk CEO explains why new GLP-1 pill expands access to the weight loss drugs

Novo Nordisk CEO Mike Doustdar told Jim Cramer about developments in obesity treatment.

·United States
Read Full Article
PerthNowPerthNow
+2 Reposted by 2 other sources
Center

Demand for weight-loss pills predicted to expand

An oral version of weight-loss medication Wegovy could expand treatment to groups like men and younger patients, a Novo Nordisk executive ​says.

·City of Perth, Australia
Read Full Article
adressa.noadressa.no
Reposted by
banett.nobanett.no

Sales Record for Diet Pills

The diet drug Wegovy had sales of 2.2 billion kroner in this country last year, according to figures from the Norwegian Pharmacy Association.

Read Full Article
TV 2TV 2

Diet Pill with Huge Sales

The diet drug Wegovy has set a new sales record in Norway.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 50% of the sources are Center
50% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

TV 2 broke the news in on Monday, January 12, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

Jim Cramer icon

Jim Cramer

Obesity icon

Obesity

GLP-1 icon

GLP-1

Norway icon

Norway

Health & Medicine icon

Health & Medicine

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal